Cel­gene goes all-out on neu­rode­gen­er­a­tion and Alzheimer’s, trig­ger­ing block­buster deal with $150M in cash for Prothena

Af­ter qui­et­ly build­ing up an ex­pe­ri­enced team of in­ves­ti­ga­tors to tack­le neu­rode­gen­er­a­tion, Cel­gene has be­gun to ag­gres­sive­ly in-li­cense new drugs that can go af­ter Alzheimer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER